• LAST PRICE
    3.7800
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.0000/ 0
  • Ask / Lots
    4.0000/ 2
  • Open / Previous Close
    0.0000 / 3.7800
  • Day Range
    ---
  • 52 Week Range
    Low 3.3500
    High 23.1000
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 3.71
TimeVolumeCMPI
09:35 ET1733.71
10:02 ET4023.71
10:44 ET5023.75
10:47 ET1003.7
10:58 ET3003.7004
11:02 ET1003.64
11:16 ET5003.7
11:23 ET5003.6915
11:39 ET2003.7268
12:01 ET2003.7859
12:03 ET3003.69
12:39 ET3003.7911
12:42 ET10643.7405
12:55 ET4003.71
01:06 ET1003.76
01:33 ET6003.785
03:33 ET1003.785
03:50 ET1003.7999
03:51 ET4273.8
03:55 ET1003.785
03:57 ET1003.79
04:00 ET1783.78
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCMPI
Checkmate Pharmaceuticals Inc
81.8M
-1.4x
---
United StatesAPRE
Aprea Therapeutics Inc
82.0M
-1.8x
---
United StatesIMRA
Imara Inc
80.1M
-1.2x
---
United StatesFRLN
Freeline Therapeutics Holdings PLC
85.6M
0.0x
---
United StatesENSC
Ensysce Biosciences Inc
77.4M
-5.5x
---
United StatesPSTI
Pluristem Therapeutics Inc
77.0M
-1.3x
---
As of 2021-12-08

Company Information

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing its technology to harness the power of the immune system to combat cancer. The Company’s product candidate, CMP-001 is a Toll-like receptor 9 (TLR9) agonist delivered as a biologic virus-like particle (VLP) utilizing a CpG-A oligonucleotide as a key component. CMP-001 is based on a therapeutic approach, which consists of two components, a capsid protein, which is produced by fermentation, and is derived from a QBeta Ribonucleic acid (RNA) bacteriophage; and a CpG-A deoxyribonucleic acid (DNA) oligonucleotide, which is manufactured by solid phase synthesis. These two components are combined together under controlled conditions where they self-assemble to form the VLP.

Contact Information

Headquarters
245 Main Street, 2Nd FloorCAMBRIDGE, MA, United States 02142
Phone
978-503-2124
Fax
302-655-5049

Executives

Independent Chairman of the Board
Michael Powell
Interim President, Interim Chief Executive Officer, Director
Alan Fuhrman
Chief Financial Officer
Robert Dolski
Chief Scientific Officer
Arthur Krieg
General Counsel
Katherine Eade

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$81.8M
Revenue (TTM)
$0.00
Shares Outstanding
21.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.73
Book Value
$5.81
P/E Ratio
-1.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.